Preliminary Results of Low-Dose CT as a Screening Tool for Early Stage Lung Cancer

CHEST Journal ◽  
2016 ◽  
Vol 149 (4) ◽  
pp. A281
Author(s):  
Huiming Wang ◽  
Jiajun Teng ◽  
Yanwei Zhang ◽  
Qunhui Chen ◽  
Jianding Ye ◽  
...  
2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e13159-e13159
Author(s):  
Kun Zhang ◽  
Zhoufeng Wang ◽  
Zhe Li ◽  
Jingyi Lu ◽  
Jun Min ◽  
...  

e13159 Background: Lung cancer is one of the most common forms of cancer and is responsible for approximately 1.8 million deaths per year worldwide. The current 5-year survival rate for lung cancer is only 18%; however, this improves to 56% if the cancer is detected early. While low-dose CT scans have shown promise as an early detection method, only 16% of lung cancer is currently detected at an early stage. We therefore set out to develop a non-invasive blood-based screening assay to identify lung cancer at an early stage using ctmDNA (circulating tumor methylated DNA haplotypes). Methods: Blood samples were prospectively collected from two partner hospitals from 325 healthy individuals and 116 individuals diagnosed with lung nodules by low-dose CT scan in EDTA or Streck BCT tubes and immediately separated into plasma. Patients with lung nodules that appeared cancerous then underwent surgical resection, and cancer diagnosis was confirmed via pathology. Patients were matched between healthy and cancer groups by age, sex, and smoking status. Plasma samples were processed using the Singlera Genomics LUNA assay, a targeted bisulfite sequencing method which identifies methylation haplotype patterns related to early-stage lung cancer. 241 samples were used to train a classification model based on pathology results, and 200 samples were used as a test set to validate the model. Results: In the independent test set, the LUNA assay was able to show a sensitivity of 91.9% to detect early-stage lung cancer with a specificity of 93.3% in healthy patients. Even patients with stage Ia lung cancer were readily detected by the LUNA assay (sensitivity of 91.7%). Conclusions: We have shown that ctmDNA can be utilized to non-invasively screen for early-stage lung cancer with high sensitivity and specificity, paving the way for a blood-based lung cancer early screening assay.


2021 ◽  
Author(s):  
Monica Saravana Vela ◽  
Joseph Berei ◽  
Katrina Dovalovsky ◽  
Shylendra Sreenivasappa ◽  
Joseph Ross ◽  
...  

2021 ◽  
Vol 16 (3) ◽  
pp. S264-S265
Author(s):  
F. Xu ◽  
L. Yang ◽  
C. Liu ◽  
J. Ying ◽  
Y. Wang

Author(s):  
Guangyao Wu ◽  
Arthur Jochems ◽  
Turkey Refaee ◽  
Abdalla Ibrahim ◽  
Chenggong Yan ◽  
...  

Abstract Introduction Lung cancer ranks second in new cancer cases and first in cancer-related deaths worldwide. Precision medicine is working on altering treatment approaches and improving outcomes in this patient population. Radiological images are a powerful non-invasive tool in the screening and diagnosis of early-stage lung cancer, treatment strategy support, prognosis assessment, and follow-up for advanced-stage lung cancer. Recently, radiological features have evolved from solely semantic to include (handcrafted and deep) radiomic features. Radiomics entails the extraction and analysis of quantitative features from medical images using mathematical and machine learning methods to explore possible ties with biology and clinical outcomes. Methods Here, we outline the latest applications of both structural and functional radiomics in detection, diagnosis, and prediction of pathology, gene mutation, treatment strategy, follow-up, treatment response evaluation, and prognosis in the field of lung cancer. Conclusion The major drawbacks of radiomics are the lack of large datasets with high-quality data, standardization of methodology, the black-box nature of deep learning, and reproducibility. The prerequisite for the clinical implementation of radiomics is that these limitations are addressed. Future directions include a safer and more efficient model-training mode, merge multi-modality images, and combined multi-discipline or multi-omics to form “Medomics.”


2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Seijiro Sato ◽  
Masaya Nakamura ◽  
Yuki Shimizu ◽  
Tatsuya Goto ◽  
Terumoto Koike ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document